Biotech Values

[DewDiligence]

NLSP reverse-merges with KDST.TA:

https://www.accesswire.com/viewarticle.aspx?id=893597&lang=en

…NLS will issue its shares to the Kadimastem shareholders who, after completing the Transaction, will hold 85% of the issued and outstanding shares of NLS, and the existing shareholders of NLS will hold the remaining 15% of NLS.

…Kadimastem is developing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells.

AstroRx, Kadimastem‘s lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications

IsletRx is Kadimastem‘s treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon. IsletRx is intended to treat and potentially cure patients with insulin-dependent diabetes.

The reverse-merger enables Kadimastem, which trades on Israel’s TASE, to have a Nasdaq listing, which seems to be the sole purpose of the deal.